![]() |
市场调查报告书
商品编码
1499414
胶原蛋白疾病血管疾病市场:按产品、适应症和最终用途 - 全球预测 2024-2030Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
胶原病血管疾病市场规模预计2023年为298.3亿美元,2024年达322.1亿美元,预计2030年将达535.1亿美元,复合年增长率为8.70%。
胶原血管疾病是一组涉及支持器官和身体其他部位的富含蛋白质的组织的疾病。这种结缔组织对于皮肤、肌腱、骨骼、软骨和血管的强度、弹性和结构至关重要。胶原病血管疾病可能是遗传性的,也可能是由过度活跃的免疫系统引起的,导致身体攻击自身组织的自体免疫疾病。这些疾病通常具有通用特征,包括导致受影响器官和组织受损和功能障碍的发炎。此类别包括多种疾病,包括类风湿性关节炎、硬皮症、全身性红斑性狼疮、多发性肌炎、皮肌炎和全身性硬化症。胶原病血管疾病市场涵盖医疗解决方案的需求和供应,例如针对影响结缔组织的疾病的诊断、治疗、疗法和服务。该市场的应用包括临床诊断、治疗和持续的患者管理。最终使用者通常是医疗机构,例如医院、诊所、风湿病中心和居家照护机构。该市场也为研究和学术机构以及参与开发新治疗方法的製药和生物技术公司提供服务。影响胶原血管疾病市场需求的关键因素是:人们对胶原血管疾病的认识和理解不断提高、全球自体免疫疾病盛行率上升、医疗保健基础设施的改善以及医疗服务的可及性的改善。然而,他们面临挑战,例如与先进治疗和药物相关的高成本,以及严格的政府法规和核准流程。同时,胶原血管疾病的需求带来了一些快速增长的机会,包括基因治疗和干细胞治疗的进步,以及远端医疗、行动医疗应用和穿戴式装置在患者管理中的采用。
主要市场统计 | |
---|---|
基准年[2023] | 298.3亿美元 |
预测年份 [2024] | 322.1亿美元 |
预测年份 [2030] | 535.1亿美元 |
复合年增长率(%) | 8.70% |
区域洞察
美国因其完善的医疗基础设施、患者意识以及自体免疫疾病的高盛行率而成为心血管疾病的重要市场。专注于技术创新的大型製药企业的存在和政府的支持政策正在促进市场的扩张。在南美洲,随着医疗保健的改善和人们对这种疾病的认识不断提高,胶原蛋白血管疾病市场正在扩大。政府加强医疗保健服务和医学研究国际合作的措施预计将进一步提振市场。欧盟对 KEYWORD 的需求的特征是全民健保系统的可用性以及对研究和开发的重视。严格的药品核准规定确保了高标准的医疗服务。该地区的消费者期待最先进的治疗设施,并受到治疗的功效和安全性的驱动。包括胶原血管疾病在内的自体免疫疾病在中东呈上升趋势,发展中的医疗保健产业高度依赖国际指南和药物。非洲治疗胶原血管疾病的能力各不相同,许多地区这些疾病的盛行率很高,而且缺乏先进的治疗方法。随着向现代医疗保健体系的过渡,中国市场正在迅速扩张,政府和私营部门对医疗保健的投资不断增加,全球药品的取得也不断改善,影响着客户的需求。日本市场反映了医疗保健领域技术整合的高水平,消费者基础倾向于创新和护理品质。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在胶原病血管疾病市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对胶原血管疾病市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对他们目前在胶原病血管疾病市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[184 Pages Report] The Collagen Vascular Diseases Market size was estimated at USD 29.83 billion in 2023 and expected to reach USD 32.21 billion in 2024, at a CAGR 8.70% to reach USD 53.51 billion by 2030.
Collagen vascular diseases comprise a group of disorders that involve the protein-rich tissue that supports organs and other parts of the body. This connective tissue is essential for the strength, elasticity, and structure of skin, tendons, bones, cartilage, and blood vessels. Collagen vascular diseases can be hereditary or caused by an overactive immune system, resulting in autoimmune conditions where the body attacks its own tissues. These diseases often share common features, including inflammation, which can damage and dysfunction of affected organs and tissues. The category encompasses a variety of conditions, including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, polymyositis, dermatomyositis, and systemic sclerosis, among others. The market for collagen vascular diseases encompasses the demand and supply of medical solutions, including diagnostics, treatments, therapeutics, and services targeted towards diseases that affect connective tissue. Applications for this market include clinical diagnostics, therapeutic treatments, and ongoing patient management. End-users are typically healthcare facilities like hospitals, clinics, specialized rheumatology centers, and home care settings. This market also serves research and academic institutions and pharmaceutical and biotechnology companies involved in the development of new treatments. The key factors influencing the need for the collagen vascular diseases market include growing awareness and understanding of collagen vascular diseases, rising incidence of autoimmune diseases globally, improved healthcare infrastructure, and increased accessibility to medical services. However, the market faces challenges, such as high costs associated with advanced treatments and medications and stringent government regulations and approval processes. On the other hand, the need for collagen vascular diseases presents several burgeoning opportunities, such as ongoing advancements in gene and stem cell therapies and the adoption of telemedicine, mobile health applications, and wearables for patient management.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 29.83 billion |
Estimated Year [2024] | USD 32.21 billion |
Forecast Year [2030] | USD 53.51 billion |
CAGR (%) | 8.70% |
Regional Insights
The United States represents a significant market for collagen vascular diseases (CVDs), driven by a well-established healthcare infrastructure, patient awareness, and a high incidence of autoimmune diseases. The presence of leading pharmaceutical companies focusing on innovation, coupled with supportive government policies, contributes to market expansion. In South America, the collagen vascular diseases market is expanding as healthcare access improves and the population becomes more aware of these diseases. Government initiatives to strengthen healthcare provision and international collaborations for medical research are expected to propel the market further. The EU's need for collagen vascular diseases is characterized by the availability of universal healthcare systems and a strong focus on research and development. Stringent regulations regarding drug approvals ensure a high standard of care. Consumers in this region expect state-of-the-art treatment facilities and are driven by the effectiveness and safety profiles of treatments. The Middle East is experiencing a rise in autoimmune disorders, including collagen vascular diseases, and due to a developing healthcare sector, there is a reliance on international guidelines and medications. Africa's capacity to manage collagen vascular diseases is varied, with a greater prevalence of these conditions and a scarcity of advanced treatments in many regions. China's market is rapidly expanding with a shift towards modern healthcare systems, and increased investment in healthcare by the government and private sector, paired with greater access to global pharmaceuticals, is influencing customer needs. Japan's market reflects a high degree of technological integration in healthcare, with a consumer base inclined towards innovation and treatment quality.
Market Insights
The market dynamics represent an ever-changing landscape of the Collagen Vascular Diseases Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Collagen Vascular Diseases Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Collagen Vascular Diseases Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Quest Diagnostics and Scipher Medicine have forged a multi-year partnership to widen the scope of diagnostic capabilities for rheumatoid arthritis (RA) management, leveraging the pioneering PrismRA test. This molecular signature response classifier (MSRC) facilitates the prediction of responses to TNF inhibitor therapies, which is crucial for managing RA. Quest's service extension to include advanced RNA extraction and next-generation sequencing ensures a more efficient assessment of patient responses to TNF inhibitors. The partnership capitalizes on Quest's nationwide network for specimen collection and sophisticated logistics, thereby enhancing patient access to precision diagnostic solutions. [Published On: 2023-11-28]
FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA
Biogen has announced the FDA approval of Tofidence, the inaugural tocilizumab biosimilar authorized for use in the U.S., offering new treatment options for individuals with rheumatoid arthritis (RA) and certain juvenile arthritis conditions. This milestone promises increased healthcare savings and broader therapeutic access, according to the details provided by the manufacturer. Tofidence has been validated based on rigorous data analysis, including a phase 1 and phase 3 study, affirming its safety and efficacy as a biosimilar alternative to the reference drug Actemra. [Published On: 2023-10-02]
American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes
The American College of Rheumatology (ACR) has introduced its innovative Rheumatoid Arthritis (RA) Measures Toolkit, a comprehensive resource designed to dramatically enhance the quality of RA patient care. Emphasizing the importance of regular monitoring and individualized therapy, the toolkit offers invaluable tools, including training guides, multilingual outcome measure copies, and workflow samples, to ensure precise and effective tracking of disease activity and patient functionality. [Published On: 2023-08-09]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Collagen Vascular Diseases Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Collagen Vascular Diseases Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Apollo Health and Lifestyle Limited, Augurex Life Sciences Corporation, Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd, Getinge AB, Gilead Sciences, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, LeMaitre Vascular, Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc,, QIAGEN GmbH, Siemens AG, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.
Market Segmentation & Coverage